The National Health Service is expected to have a $49-billion deficit by 2020.
The PBM encourages step-therapy to control costs.
The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.
Domestic manufacturers are being pressured to offer domestic discounts to international clients.
The drugmaker blasted the price-control agency for being shortsighted and underestimating the industry's role in health and savings.
Subscribers will be able to use co-pay cards on Obamacare exchanges.
A wide-ranging piece recounts the pushback from oncologists that led to a decrease in the price of Zaltrap.
The short answer: we're not financially prepared for a slowly aging, healthy population, according to a recently published analysis.
AbbVie and Galapagos go after cystic fibrosis; FDA's NME approval pace slows; government shutdown could slow ad-com votes; and a report shows privately insured patients had emptier pockets in 2012 than 2011
Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards
CDC finds that non-Medicare adults make up the majority of preventable heart attack and stroke cases; a Facebook study shows groups can influence HIV screening; and a Shire ADHD drug gets a "no" from Germany
Australia's price watchdogs are assessing the value of BMS cancer drug Yervoy; why a Phase II weight drug from Zafgen could open up the category; GSK halts a Crohn's trial; and Shire extends Santaris rare-disease collaboration
GSK seeks a new ovarian cancer indication for Votrient; a bill that would extend exclusivity for some combination drugs is introduced in Congress; Otsuka's tolvaptan gets a thumbs-down from an FDA advisory committee; NICE rejects Roche's Perjeta; India tosses Herceptin patents; and China revokes Gilead's patent on Viread
Three studies take on different angles of the patient experience. Spoiler alert: no cost increases are mentioned.
GlaxoSmithKline says it is scaling back on acquisitions; Sanofi's CEO picks a regulatory fight; Maine wants to allow Ex-US meds; and New York State seeks to empower pharmacists.
A study highlights medical service trends among patients with high-deductible plans but lacks insight on health impact and long-term costs.
JAMA's look into the impact of patient centric care shows that a broader scope is needed to understand the financial and health impact of active patients and how doctors perceive what it means to be engaged with patients.
AbbVie's Niaspan pricing gets a hard look; AstraZeneca buys up heart drug and company; Valeant expands eye care portfolio with B&L; Merck halts Parkinson's study; Novo explores liraglutide weight loss results.
Doctors call out Novartis on drug prices; Aubagio shows strong top-line data in trials; and overseas docs increasingly turn to digital.
Roche is shuttering a division and eliminating 170 jobs; Doximity has added another client; a cautiously-worded study indicates antidepressants may be linked to autism; and NICE has endorsed a new use for Bayer's Xarelto.
Two studies show that it's not enough to focus on cost to alter healthcare.
CDC figures suggest patients are avoiding medications to save money, and show that out-of-pocket costs for US consumers are rising faster than those for consumers in many other countries
Execs told Booz & Co researchers that the relationships web in emerging markets needs to be deeper than one-on-one sales pitches.
A pair of studies suggests that consumers are hungry for information, and that price determines how patients perceive their risk for life-threatening conditions.
The company is beefing up its marketing staff, using an iPad-equipped mix of in-house and contracted talent.
The nonpartisan Congressional Budget Office is tallying medical savings differently, adding a new perspective to chatter about the financial implications of nonadherence and rising drug prices.
Roche closes an R&D deal for NYC, MRM gets a new address and Arizona's AG is suing McKesson.
Representatives from four states and the District of Columbia are asking Gilead to keep HIV drugs prices in check. The letter is a prelude to the FDA's August 27 review of the Quad pill.
The drugmaker's new auto-injecting epinephrine pen provides verbal cues during emergency allergic situations. It's the latest entry in a competitive market.
Corcept Therapeutics said its Cushing's syndrome drug will be launched three weeks earlier than expected.